Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 84

recruiting
3 972
countries
28
conditions
2 103

1 070 trials match your criteria

Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Study on Selexipag and Bosentan for Children with Pulmonary Arterial Hypertension

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Bosentan

Study on Imlifidase and Drug Combination for Treating Severe Goodpasture Disease in Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Study on the Effects of Obexelimab for Patients with IgG4-Related Disease

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Obexelimab

Dermatomyositis+1

Not recruiting

Study on the Effects of Enpatoran for Patients with Dermatomyositis and Polymyositis

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran

Study on the Effects of Tildacerfont and Hydrocortisone in Adults with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone

Study on Tildacerfont to Reduce Glucocorticoid Use in Adults with Classic Congenital Adrenal Hyperplasia

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone

Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Vericiguat

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Zilovertamab Vedotin

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant

Study on O15-Water for Diagnosing Coronary Artery Disease in Patients Using PET Imaging During Stress and Rest Conditions

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:O15-WATER

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.